

1 **Reappearance of Effector T Cells Predicts Successful Recovery from COVID-19**

2

3 Ivan Odak¹, Joana Barros-Martins¹, Berislav Bošnjak¹, Klaus Stahl², Sascha David³, Olaf

4 Wiesner⁴, Markus Busch², Marius M Hoepfer⁴, Isabell Pink⁴, Tobias Welte⁴, Markus

5 Cornberg^{2,5,6}, Matthias Stoll⁷, Lilia Goudeva⁸, Rainer Blasczyk⁸, Arnold Ganser⁹ Immo

6 Prinz^{1,5,6}, Reinhold Förster^{1,5,6}, Christian Koenecke,^{1,5,9*} and Christian R Schultze-Florey^{1,9*}

7 *Authors contributed equally.

8

9 Affiliations

10 ¹Institute of Immunology, Hannover Medical School, Germany

11 ²Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical
12 School, Germany

13 ³Department of Nephrology and Hypertension, Hannover Medical School, Germany

14 ⁴Department of Pneumology and German Center of Lung Research (DZL), Hannover
15 Medical School, Germany

16 ⁵Centre for Individualised Infection Medicine (CiiM), Hannover, Germany

17 ⁶Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

18 ⁷Department of Rheumatology and Immunology, Hannover Medical School, Germany

19 ⁸Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School,
20 Germany

21 ⁹Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,

22 Hannover Medical School, Germany

23

24 Corresponding author: Christian R Schultze-Florey, Carl-Neuberg-Str. 1, 30625 Hannover;

25 schultze-florey.christian@mh-hannover.de; Tel: 0049-511-532-9725

26

27 **Abstract**

28 **Background:** Elucidating the role of T cell responses in COVID-19 is of utmost importance
29 to understand the clearance of SARS-CoV-2 infection.

30 **Methods:** 30 hospitalized COVID-19 patients and 60 age- and gender-matched healthy
31 controls (HC) participated in this study. We used two comprehensive 11-color flow
32 cytometric panels conforming to Good Laboratory Practice and approved for clinical
33 diagnostics.

34 **Findings:** Absolute numbers of lymphocyte subsets were differentially decreased in COVID-
35 19 patients according to clinical severity. In severe disease (SD) patients, all lymphocyte
36 subsets were reduced, whilst in mild disease (MD) NK, NKT and $\gamma\delta$ T cells were at the level
37 of HC. Additionally, we provide evidence of T cell activation in MD but not SD, when
38 compared to HC. Follow up samples revealed a marked increase in effector T cells and
39 memory subsets in convalescing but not in non-convalescing patients.

40 **Interpretation:** Our data suggest that activation and expansion of innate and adaptive
41 lymphocytes play a major role in COVID-19. Additionally, recovery is associated with
42 formation of T cell memory as suggested by the missing formation of effector and central
43 memory T cells in SD but not in MD. Understanding T cell-responses in the context of
44 clinical severity might serve as foundation to overcome the lack of effective anti-viral
45 immune response in severely affected COVID-19 patients and can offer prognostic value as
46 biomarker for disease outcome and control.

47 **Funding:** Funded by German Research Foundation, Excellence Strategy – EXC 2155
48 “RESIST”–Project ID39087428, and DFG-SFB900/3–Project ID158989968, grants SFB900-
49 B3 to R.F., SFB900-B8 to I.P. and C.K.

50

51 **Introduction**

52 Cross-species infections are becoming more common due to increase in interlinking human
53 and animal activities, furthered by great genetic diversity of viruses¹. The threat of emerging
54 global pandemics by new virus species and/or mutants has been significantly heightened in
55 the wake of severe acute respiratory syndrome coronavirus (SARS-CoV)² and Middle East
56 respiratory syndrome coronavirus (MERS-CoV)³ outbreaks. Both of these zoonotic
57 coronaviruses are highly infectious and have high fatality rates⁴. In December 2019, another
58 type of coronavirus, later named SARS-CoV-2, was reported in patients with pneumonia,
59 causing coronavirus disease 2019 (COVID-19)⁵. SARS-CoV-2 has since turned into a global
60 pandemic with a total of 3 925 815 confirmed cases of COVID-19 and 274 488 fatal cases as
61 of May 10th 2020 according to recent WHO situation report⁶.

62 Since the onset of the SARS-CoV-2 pandemic, research focuses on immune profiling of the
63 infection, striving towards better patient management and treatment. As it is the case in the
64 majority of viral infections, key players in battling the SARS-CoV-2 appear to be NK, T and
65 B cells^{7,8}. According to available data⁹⁻¹¹, COVID-19 patients with severe disease have
66 increased levels of C-reactive protein and IL-6 as well as augmented neutrophil counts but
67 reduced lymphocyte counts in blood. Moreover, NK cells and CD8⁺ T cells in COVID-19
68 patients appear to be functionally exhausted, indicated by increased expression of NKG2A⁸
69 and lower production of IFN- γ , TNF- α and IL-2¹². Nevertheless, it is unclear whether and
70 how profiling of T cell responses can be used as prognostic biomarker for disease outcome
71 and control. Furthermore, no data is available on the role of $\gamma\delta$ T cells in anti-SARS-CoV-2
72 immune responses, although it has been demonstrated that these cells contribute to immunity
73 against SARS-CoV and other viruses¹³⁻¹⁵.

74 In the present study we analysed dynamics of NK, NKT, $\alpha\beta$ and $\gamma\delta$ T cells subsets in the
75 peripheral blood of patients with mild and severe COVID-19 compared to gender- and age-

76 matched controls. To reliably assess major lymphocyte subsets' profiles during successful
77 immune response against SARS-CoV-2 infection, we developed two comprehensive Good
78 Laboratory Practice (GLP)-conforming 11-color flow cytometric panels approved for clinical
79 diagnostics. Using those panels, we examined the composition of seven major lymphocyte
80 populations in patients with mild and severe COVID-19 and followed formation of effector
81 and memory $\alpha\beta$ and $\gamma\delta$ T cells from consecutive blood samples of patients who did or did not
82 clinically improve. We found that recovery from COVID-19 was closely associated with
83 expansion and differentiation/maturation in $\alpha\beta$, but not $\gamma\delta$ T cells.

84

85 **Materials and Methods**

86 *Study participants*

87 Patients with PCR-confirmed SARS-CoV-2 infection were recruited at Hannover Medical
88 School from March 30th until April 16th 2020. Based on the clinical presentation, disease
89 was classified as “mild” or “severe” for every single patient at admission. Mild disease was
90 defined for patients with stable lung parameters with no oxygen flow or of up to 3 liters per
91 minute. In contrast, severe disease was defined as oxygen flow equal or greater than 6 liters
92 per minute to maintain a $SpO_2 > 90\%$, or non-invasive or invasive ventilation. Patient
93 characteristics are shown in **Table 1**. To assess the impact of infection on lymphocyte
94 subsets, age- and gender-matched healthy controls (HC) were selected for every patient in a
95 2:1 control-to-patient ratio. Those patients of 56 years of age and older were gender-matched
96 to the group of 56-69 year old healthy controls. Healthy controls were recruited through the
97 Institute of Transfusion Medicine in October and November 2019, prior to SARS-CoV-2
98 outbreak. Healthy control characteristics are listed in **Supplementary Table 1**. The study
99 was approved by the institutional review board at Hannover Medical School
100 (#9001_BO_K2020 and #8606_BO_K2019) and informed consent was obtained from all
101 patients and healthy controls.

102

103 *Flow cytometry*

104 EDTA-anticoagulated whole blood was stained with the antibodies as listed in
105 **Supplementary Table 2**. For analysis of absolute cell counts BD TruCount™ tubes were
106 used, and cells were analyzed in a lyse-no-wash fashion according to manufacturer’s
107 instructions. For analysis of activation markers, cells were analyzed in a lyse-wash fashion.
108 Stained cells were acquired on BD FACS Lyric, standardized for clinical cell analysis. Flow
109 cytometry data were analysed using FCSExpress 7 (De Novo Software).

110

111 *Statistical analysis*

112 Data were analyzed using Prism 7.05 (GraphPad). For group comparisons two-tailed student t

113 test or Mann-Whitney U test were used where applicable; for longitudinal changes two-tailed

114 paired t test was used.

115

116 **Results**

117 Our cohort of 30 hospitalized COVID-19 patients was predominantly male (80%), of older
118 age (mean 61 years, range 19-91) and 93% had mostly mild pre-existing medical conditions.
119 Patients were classified upon admission as mild (n=15) and as severe (n=15, **Table 1**).
120 Patients with severe disease (SD) were slightly older and had a higher proportion of male
121 gender, although both not significantly different from patients with mild disease (MD).
122 Characteristics of healthy controls (HC) are listed in **Supplementary Table 1**.

123

124 *Severe COVID-19 patients show reduced counts of lymphocyte subsets*

125 Using BD TruCount™ technology, we observed significantly reduced lymphocyte numbers
126 in COVID-19 patients, inversely correlated with disease severity (**Supplementary Fig. 1**).

127 To further characterize the composition of the lymphocyte pool, we developed two
128 comprehensive GLP-conforming 11-color comprehensive flow cytometric mAb panels,
129 which were approved in-house for clinical diagnostics. The first panel of mAb used in this
130 study (**Supplementary Fig. 2A**) allowed us to profile NK, NKT, B, $\alpha\beta$ and $\gamma\delta$ T cell numbers
131 in blood of HC and COVID-19 patients with MD or SD. Compared to MD patients, we found
132 strikingly lower numbers of NK, NKT, $\gamma\delta^-$, and $CD8^+$ cells in the blood of SD COVID-19
133 patients (**Fig. 1**). $\gamma\delta^+V\gamma9^+$ cells are reported to be responsive to phospho-antigens^{16,17} and we
134 noticed a trend to reduced numbers of $\gamma\delta^+V\gamma9^+$ in SD patients compared to MD (P=0.0502,
135 two-tailed Student's t test). In addition, all subsets investigated were significantly reduced in
136 SD patients compared to HC (**Fig. 1**). Interestingly, MD patients had similar levels of NK,
137 NKT, $\gamma\delta^-$, conventional $CD4^+$ ($CD4_{conv}$) and $CD8^+$ cells as compared to HC. Of note, both
138 MD and SD patients showed a marked reduction of regulatory T cells (**Fig. 1**). Together,
139 these data provide a detailed depiction of reduced lymphocyte subsets in mild and severe

140 COVID-19 patients, employing certified counting beads for analysis of absolute cell
141 numbers.

142

143 *Patients with severe COVID19 infection lack generation of effector and central memory $\alpha\beta$*
144 *$CD4_{conv}$ and $CD8^+$ cells*

145 To characterize the involvement of different subsets of $\alpha\beta$ $CD4_{conv}$, $\alpha\beta$ $CD8^+$, and $\gamma\delta$ T cells
146 based on their antigen experience^{18,19}, we developed a staining panel dedicated to identifying
147 four distinct populations based on CD62L and CD45RA expression (**Supplementary Fig.**
148 **2B**). Looking at the distribution of $CD45RA^+CD62L^+$ on conventional $CD4^+$ T cells
149 ($CD4_{conv}$) we defined naïve ($CD4_{naïve}$, $CD45RA^+CD62L^+$), effector/effector memory
150 ($CD4_{eff/em}$, $CD45RA^-CD62L^-$), terminally differentiated cells ($CD4_{temra}$, $CD45RA^+CD62L^-$)
151 and central memory ($CD4_{cm}$, $CD45RA^-CD62L^+$). Based on this allocation, we observed a
152 marked decrease of $CD4_{eff/em}$ in SD compared to MD patients (**Fig. 2A**). In addition, both
153 COVID-19 groups had increased frequencies of $CD4_{temra}$ and decreased $CD4_{eff/em}$ compared
154 to HC (**Fig. 2A**). The same observations were made when absolute cell counts were
155 calculated (**Supplementary Fig. 3A**). Investigating the memory phenotypes of $\alpha\beta$ $CD8^+$ cells
156 revealed a striking increase in frequencies of $CD8_{eff/em}$ cells, as well as a decrease of $CD8_{naïve}$
157 T cells in MD compared to HC and SD (**Fig. 2B**). These observations indicate successful
158 mobilization and/or differentiation of cytotoxic lymphocytes (CTL) in MD patients.
159 Compared to MD, patients with SD had higher frequency of $CD8_{naïve}$ T cells and lower
160 frequency of $CD8_{eff/em}$ cells, implying deficits in successfully mounting CTL responses in SD
161 patients or increased recruitment to the peripheral organs. Furthermore, we found similar
162 frequencies of $CD8_{cm}$ and $CD8_{temra}$ in samples from MD and HC but a decrease of these cell
163 populations in SD (**Fig. 2B**), again hinting towards an impaired CTL response in patients
164 with SD. The absolute numbers of CD8 memory subsets was changed similarly with the

165 exception of CD8_{naïve} T cells in SD which were similar to those of MD patients
166 **(Supplementary Fig. 3B)**.

167

168 *γδ T cells from COVID-19 patients exhibit a distinct memory signature*

169 Human γδ T cells have been shown to be important for regulating immune responses to
170 CMV, HCV and SARS-CoV infections¹³⁻¹⁵. Using a panel of 11 specific mAb
171 **(Supplementary Fig. 2B)**, we found that expression of CD45RA and CD62L on γδ cells
172 would also allow their categorization into four subsets as defined above for αβ T cells.
173 Interestingly, we revealed a marked increase in both frequencies and absolute cell numbers of
174 naïve-like γδ (γδ_{naïve-1}) cells, and a proportional decrease in effector-like γδ (γδ_{eff-1}) cells in
175 both groups of patients suffering from COVID-19 **(Fig. 3)**. These data suggest that γδ_{eff-1} T
176 cells might be recruited from the blood to peripheral organs such as the lungs of COVID-19
177 patients and that these cells might participate in the immune response against SARS-CoV-2
178 infection.

179

180 *Early establishment of T cell memory suggests better clinical outcome*

181 To evaluate the hypothesis that convalescence from COVID-19 is related to establishment of
182 successful T cell immunity, we evaluated the signature of CD4_{conv} and CD8⁺ cells based on
183 the clinical course of the disease. To that end, we collected longitudinal samples of 5 MD and
184 12 SD patients. We defined convalescence as an improvement of lung function (e.g.
185 reduction of oxygen flow or ventilation parameters), excluding transient variations, thus only
186 taking long-lasting clinical improvement in consideration. Convalescence rate in MD and SD
187 patients occurred at similar frequencies (2/5 vs 5/12) while the period of follow-up was
188 slightly longer in SD patients without reaching statistical significance (SD: 10.08 vs MD:
189 7.60 days; **Table 1**). Therefore, we re-grouped the MD and SD patients into convalescing

190 (n=7) and non-convalescing patients (n=10). In all convalescing patients irrespective of the
191 disease severity, we observed a strong decrease of the frequency of CD4_{naïve} and a marked
192 increase of CD4_{eff/em} and CD4_{cm} populations (**Fig. 4A**) suggesting a turnover of naïve to
193 memory/effector cells. The same observations were made for all convalescing patients
194 regarding the relative distribution of naïve and memory CD8⁺ T cell subsets (**Fig. 4B**).
195 Notably, no significant changes could be observed for any of the CD4_{conv} and CD8⁺
196 subpopulations in non-convalescing patients (**Fig. 4**). We also failed to observe any
197 significant alterations in frequencies of the different subtypes of $\gamma\delta$ cells in relation to disease
198 clearance (**Supplementary Fig. 4**). We therefore suggest that the alterations observed for
199 CD4_{conv} and CD8⁺ $\alpha\beta$ T cells in convalescing patients that recover from COVID-19 are
200 linked to differentiation of effector/memory $\alpha\beta$ T cells.

201

202 **Discussion**

203 From an immunological perspective, adaptive anti-viral responses occur in two layers. First, a
204 NK, NKT and CD8⁺ T cell response is programmed to prevent the disease to proceed to a
205 severe phase. Second, helper T cells are poised to influence and program B cells for specific
206 neutralizing antibody formation, conferring long-lasting humoral immunity²⁰. The
207 establishment of immunity to SARS-CoV-2 has been associated with the presence of
208 neutralizing IgG antibodies in blood sera^{21,22}. However, some viruses such as influenza are
209 notoriously known to be resilient to establish humoral immunity²³. This might also be the
210 case for SARS-CoV-2. We therefore studied changes in T cell subsets in COVID-19 patients.

211 Applying two comprehensive GLP-conforming 11-color flow cytometric panels approved for
212 clinical diagnostics, this prospective single-center study from Germany identified profound
213 changes in absolute numbers in seven different lymphocyte subsets in hospitalized COVID-
214 19 patients with mild and severe disease. These findings were in line with and extended the
215 current literature on COVID-19-induced lymphocytopenia⁹⁻¹¹. Additionally, we revealed
216 changes in the formation of different T memory cell subsets comparing mildly and severely
217 affected COVID-19 patients with healthy controls. Moreover, in a longitudinal approach we
218 showed that convalescing – but not non-convalescing – patients develop increased
219 frequencies of different subsets of CD4_{conv} and CD8⁺T cell showing memory/effector
220 phenotypes. Together, our findings indicate that mounting an efficient T cell response allows
221 hospitalized patients to combat and overcome SARS-CoV-2 infections.

222 In agreement with recent reports, we observed a general decrease of lymphocytes in all
223 COVID-19 patients that was more pronounced in severe cases⁸⁻¹⁰. Such a reduction of
224 immune cells in the blood of SD patients might be due to several causes. It is conceivable that
225 infection with SARS-CoV-2 directly affects differentiation and/or production in and release

226 from primary lymphoid organs. Although this virus in general is not suspected to infect and
227 destroy immune cells or their progenitors to a large degree, it seems possible that such effects
228 might be secondary and caused by massive release in inflammatory mediators as a response
229 to the infection^{9,10}. Alternatively, failure to observe lymphocytes in the blood might be due to
230 their homing/recruitment to the lung or other infected organs¹¹. COVID-19 patients with a
231 mild clinical course did not show reduction in NK, NKT and $\gamma\delta$ T cells counts. NK cells are
232 part of the innate immunity and their significance in clearance of viral infections has been
233 well documented^{24,25}. It is thus reasonable to assume that these cells contribute to keeping the
234 disease from progressing, as suggested before⁸. The observation that these innate and innate-
235 like immune cells are present in regular numbers at early stages of the disease might also
236 indicate that this arm of the immune system helps to contain early virus infection.

237 Compared to HC, COVID-19 patients showed already altered effector/effector memory and
238 naïve T cell proportions at hospital admission. Increased frequencies of effector and memory
239 populations in MD, but not SD, suggest that MD patients already launched a broad adaptive
240 immune response at that time point, whilst this was presumably not the case in severely
241 affected patients. Along the same line, a shift towards further activation of $\alpha\beta$ T cells
242 coincided with convalescence, also hinting at the presence of SARS-CoV-2 responsive T
243 cells. These findings are in line with very recent reports describing the role of T cell
244 immunity in COVID-19 patients²⁶⁻²⁹.

245 Data of the present study highlight the role of T cells in successfully controlling SARS-CoV-
246 2 infections and holds implications for vaccine design and assessment of successful immune
247 response in vaccine trials. Furthermore, comprehensive lymphocyte subset analyses by flow
248 cytometry can be easily implemented and might serve as a biomarker for disease outcome
249 and control.

250

251 Acknowledgements:

252 We thank Jolanta Adolf, Christine Garen, Ellen Hebold, Bianca Krüger and Kerstin Schantl
253 for their support with the experiments. We thank Melanie Drenker and Daniela Garve for
254 their support with the clinical data analysis.

255

256 Author contributions: IO, CK and CRSF designed the study, KS and SD obtained written
257 informed consent from all patients, LG obtained written informed consent from all healthy
258 controls, CRSF and IO performed experiments and analysed experimental data; IO, CRSF,
259 ImP, RF and CK interpreted the data, IO and CRSF wrote the manuscript, JBM, BB, KS, SD,
260 OW, MB, MMH, IsP, TW, MC, MS, LG, RB, AG, ImP, RF and CK reviewed and edited the
261 manuscript.

262

263 Declaration of interests

264 All authors declare no conflict of interest regarding this work.

265

266 References:

- 267 1 Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: The Role
268 of Super-Spreaders in Infectious Disease. *Cell Host Microbe* 2015; **18**: 398–401.
- 269 2 Drosten C, Günther S, Preiser W, *et al.* Identification of a novel coronavirus in patients
270 with severe acute respiratory syndrome. *N Engl J Med* 2003; **348**: 1967–76.
- 271 3 Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM.
272 Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J*
273 *Med* 2012; **367**: 1814–20.
- 274 4 Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev*
275 *Microbiol* 2019; **17**: 181–92.
- 276 5 Zhu N, Zhang D, Wang W, *et al.* A novel coronavirus from patients with pneumonia in
277 China, 2019. *N Engl J Med* 2020; **382**: 727–33.
- 278 6 WHO. Coronavirus Disease 2019. <https://covid19.who.int/> (accessed May 10, 2020).
- 279 7 Braun J, Loyal L, Frentsch M, Wendisch D, Georg P. Presence of SARS-CoV-2-
280 reactive T cells in COVID-19 patients and healthy donors. *medRxiv* 2020.
281 DOI:<https://doi.org/10.1101/2020.04.17.20061440>.
- 282 8 Zheng M, Gao Y, Wang G, *et al.* Functional exhaustion of antiviral lymphocytes in
283 COVID-19 patients. *Cell Mol Immunol* 2020; : 7–9.
- 284 9 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel
285 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497–506.
- 286 10 Yang X, Yu Y, Xu J, *et al.* Clinical course and outcomes of critically ill patients with
287 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,

- 288 observational study. *Lancet Respir Med* 2020; **2600**: 1–7.
- 289 11 Xu Z, Shi L, Wang Y, *et al.* Pathological findings of COVID-19 associated with acute
290 respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420–2.
- 291 12 Qin C, Zhou L, Hu Z, *et al.* Dysregulation of immune response in patients with
292 COVID-19 in Wuhan, China. *Clin Infect Dis* 2020; **53**: 1689–99.
- 293 13 Ravens S, Schultze-Florey C, Raha S, *et al.* Human $\gamma\delta$ T cells are quickly reconstituted
294 after stem-cell transplantation and show adaptive clonal expansion in response to viral
295 infection. *Nat Immunol* 2017; **18**: 393–401.
- 296 14 Poccia F, Agrati C, Castilletti C, *et al.* Anti-Severe Acute Respiratory Syndrome
297 Coronavirus Immune Responses: The Role Played by V γ 9V δ 2 T Cells. *J Infect Dis*
298 2006; **193**: 1244–9.
- 299 15 Ravens S, Hengst J, Schlapphoff V, *et al.* Human $\gamma\delta$ T cell receptor repertoires in
300 peripheral blood remain stable despite clearance of persistent hepatitis C virus
301 infection by direct-acting antiviral drug therapy. *Front Immunol* 2018; **9**.
302 DOI:10.3389/fimmu.2018.00510.
- 303 16 Constant P, Davodeau F, Peyrat MA, *et al.* Stimulation of human $\gamma\delta$ T cells by
304 nonpeptidic mycobacterial ligands. *Science (80-)* 1994; **264**: 267–70.
- 305 17 Tanaka Y, Tanaka Y, Bloom BR, Morita CT, Brenner MB, Nieves E. Natural and
306 synthetic non-peptide antigens recognized by human $\gamma\delta$ T cells. *Nature* 1995; **375**:
307 155–8.
- 308 18 Mangare C, Tischer-Zimmermann S, Riese SB, *et al.* Robust identification of suitable
309 T-cell subsets for personalized CMV-specific T-cell immunotherapy using CD45RA

- 310 and CD62L microbeads. *Int J Mol Sci* 2019; **20**. DOI:10.3390/ijms20061415.
- 311 19 Martin MD, Badovinac VP. Defining memory CD8 T cell. *Front Immunol* 2018; **9**: 1–
312 10.
- 313 20 Shi Y, Wang Y, Shao C, *et al.* COVID-19 infection: the perspectives on immune
314 responses. *Cell Death Differ* 2020; : 1451–4.
- 315 21 Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-
316 19. *Nat Rev Immunol* 2020; : 1–3.
- 317 22 Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV - A
318 target for vaccine and therapeutic development. *Nat Rev Microbiol* 2009; **7**: 226–36.
- 319 23 Bahadoran A, Lee SH, Wang SM, *et al.* Immune responses to influenza virus and its
320 correlation to age and inherited factors. *Front Microbiol* 2016; **7**: 1–11.
- 321 24 Van Der Vliet HJJ, Pinedo HM, Von Blomberg BME, Van Den Eertwegh AJM,
322 Scheper RJ, Giaccone G. Natural killer T cells. *Lancet Oncol* 2002; **3**: 574.
- 323 25 Parham P, Guethlein LA. Genetics of Natural Killer Cells in Human Health, Disease,
324 and Survival. *Annu Rev Immunol* 2018; **36**. DOI:10.1146/annurev-immunol-042617-
325 053149.
- 326 26 Weiskopf D, Schmitz KS, Raadsen MP, *et al.* Phenotype of SARS-CoV-2-specific T-
327 cells in COVID-19 patients with acute respiratory distress syndrome. *medRxiv* 2020; :
328 2020.04.11.20062349.
- 329 27 Ni L, Ye F, Cheng M-L, *et al.* Detection of SARS-CoV-2-specific humoral and
330 cellular immunity in COVID-19 convalescent individuals. *Immunity* 2020; published
331 online May. DOI:10.1016/j.immuni.2020.04.023.

332 28 Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence
333 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune
334 Responses to SARS-CoV-2. *Cell Host Microbe* 2020; **27**: 671-680.e2.

335 29 Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine
336 targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV
337 Immunological Studies. *Viruses* 2020; **12**. DOI:10.3390/v12030254.

338

339

340 **Table 1: Patients' Characteristics**

341 Abbreviations: PEMC: pre-existing medical conditions, cv: cardio vascular, m: male, f:

342 female, NA: not available, *: days after onset of symptoms

ID	Severity	Age	Gender	PEMC	cv PEMC	Symptoms	First Sampling*	Con- valescence	Convalescence Sampling*
001	mild	71	m	no	no	Fever, malaise	13	NA	NA
002	mild	68	m	yes	yes	Fever, diarrhea	13	NA	NA
003	mild	64	m	yes	yes	Malaise	14	NA	NA
012	mild	48	f	yes	no	Fever, dry cough, dyspnea	8	NA	NA
013	mild	85	m	yes	yes	Fever, dry cough	4	yes	17
014	mild	51	m	yes	yes	Fever, myalgia	16	NA	NA
016	mild	91	m	yes	yes	Dry cough, malaise	9	no	12
019	mild	48	f	yes	no	Dry cough	9	NA	NA
020	mild	57	f	yes	yes	Dyspnea, myalgia, diarrhea, emesis	8	NA	NA
021	mild	48	m	yes	yes	Fever, dry cough, myalgia	3	NA	NA
022	mild	75	m	yes	yes	Fever	8	no	18
023	mild	60	m	yes	yes	Dry cough, myalgia, cephalgia	10	NA	NA
027	mild	83	f	yes	yes	Fever, dry cough, dyspnea, malaise	5	yes	12
028	mild	42	m	yes	no	Nausea, emesis	3	NA	NA
031	mild	79	m	yes	yes	Diarrhea, nausea, emesis	2	no	7
004	severe	75	f	yes	yes	Fever, dry cough, dyspnea	7	yes	17
005	severe	60	m	yes	yes	Fever, dry cough	20	NA	NA
006	severe	51	m	yes	no	Fever, diarrhea, nausea	12	yes	19
007	severe	60	m	yes	no	Fever, dry cough, diarrhea	16	no	33
008	severe	56	m	yes	yes	Fever, dry cough, dyspnea	19	no	26
009	severe	68	m	yes	no	Dry cough, diarrhea	18	yes	25
010	severe	69	m	yes	yes	Dry cough, dyspnea	21	no	38
011	severe	45	m	yes	yes	Dry cough, dyspnea	5	no	12
015	severe	47	m	yes	yes	Fever, dry cough, dyspnea	16	no	31
017	severe	19	m	yes	no	Malaise	5	yes	19
018	severe	82	f	yes	yes	Dry cough	7	NA	NA
025	severe	65	m	yes	yes	Fever, dry cough, dyspnea	8	yes	16
026	severe	71	m	yes	yes	Fever, dry cough	13	no	18
029	severe	53	m	yes	no	Fever, dry cough, diarrhea, nausea	8	no	15
030	severe	39	m	no	no	Fever, dyspnea	32	NA	NA

343

344 Figure Legends:

345 Figure 1: Absolute numbers of lymphocyte subsets in healthy controls and mild and severe
346 COVID-19 patients.

347 Lines represent median. Statistical analysis was performed by Mann-Whitney U-test or
348 Student's t test where applicable. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$; ns:
349 not significant; HC: Healthy Control; MD: Mild Disease; SD: Severe Disease.

350

351 Figure 2: Mild COVID-19 disease is paralleled by increased levels of effector and memory T
352 cells.

353 (A) Gated on CD4_{conv}. (B) Gated on CD8⁺ T cells. Lines represent median. Statistical
354 analysis was performed by Mann-Whitney U-test or Student's t test where applicable.
355 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$; ns: not significant; HC: Healthy
356 Control. MD: Mild Disease; SD: Severe Disease.

357

358 Figure 3: $\gamma\delta$ T cells from COVID-19 patients exhibit a distinct memory signature.

359 (A) Gated on $\gamma\delta$ T cells. (B) Absolute numbers of $\gamma\delta$ T cell subpopulations. Lines represent
360 median. Statistical analysis was performed by Mann-Whitney U-test or Student's t test where
361 applicable. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$; HC: Healthy Control. MD:
362 Mild Disease; SD: Severe Disease.

363


364 Figure 4: Increase of effector/memory T cells suggests better clinical outcome.

365 (A) Gated on CD4_{conv}. (B) Gated on CD8⁺. Blue diamonds represent mild disease and red
366 diamonds severe disease patients upon admission. Statistical analysis was performed paired
367 Student's t test. *p < 0.05, **p < 0.01, ***p < 0.001; ns: not significant.

368

369 Figures:

Figure 1



370

Figure 2




Figure 3





Figure 4



373

374